Moderna, Inc. (NASDAQ:MRNA)

PRESS RELEASE

published on 05/02/2024 at 12:30, 2 years 5 months ago

Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Moderna, Inc. reports Q1 revenues of $167 million, GAAP net loss of $1.2 billion, and diluted EPS of $(3.07). Company prepares for RSV vaccine and Spikevax® 2024-2025 formula launches, with expected product sales of $4 billion in 2024

Moderna Inc. Net Loss RSV Vaccine Q1 Revenues Spikevax 2024-2025 Formula
BRIEF

published on 04/25/2024 at 13:05, 2 years 5 months ago

Moderna to Present Diverse Research Studies at ESCMID Global Congress

COVID-19 Vaccine Moderna Vaccine Research Influenza Vaccine ESCMID Congress
PRESS RELEASE

published on 04/25/2024 at 13:00, 2 years 5 months ago

Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress
Moderna, Inc. to present data on COVID-19, influenza, respiratory syncytial virus, and cytomegalovirus vaccines at ESCMID Global Congress in Barcelona, Spain

COVID-19 Moderna Inc. Barcelona Vaccines ESCMID Global Congress
BRIEF

published on 04/24/2024 at 14:05, 2 years 5 months ago

Moderna Collaborates with OpenAI to Enhance mRNA Medicines Using Advanced AI

Healthcare Innovation MRNA Technology Moderna OpenAI AI Collaboration
PRESS RELEASE

published on 04/24/2024 at 14:00, 2 years 5 months ago

Moderna and OpenAI Collaborate To Advance mRNA Medicine
Moderna and OpenAI collaborate to integrate generative AI tools, like ChatGPT Enterprise, into operations to enhance AI culture and augment employee roles for maximum impact on patients

Generative AI Machine Learning Moderna OpenAI ChatGPT Enterprise
BRIEF

published on 04/17/2024 at 13:05, 2 years 5 months ago

Moderna to Present Q1 2024 Financial Results in May

Financial Results Conference Call Webcast Moderna Q1 2024
PRESS RELEASE

published on 04/17/2024 at 13:00, 2 years 5 months ago

Moderna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
Moderna, Inc. will host a live conference call to report Q1 2024 financial results and provide a corporate update. Moderna is a leader in mRNA medicine revolutionizing disease treatment

Financial Results Conference Call Corporate Update Moderna Inc. MRNA Medicine
BRIEF

published on 04/03/2024 at 17:05, 2 years 6 months ago

Moderna's mRNA Therapy for Propionic Acidemia Shows Promise in Early-Stage Trial

Gene Therapy Clinical Trial Moderna MRNA Therapy Propionic Acidemia
PRESS RELEASE

published on 04/03/2024 at 17:00, 2 years 6 months ago

Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
Moderna, Inc. announced interim data for mRNA-3927 therapy for propionic acidemia published in Nature, showing signs of clinical benefit and safety. Ongoing global trial evaluates safety and efficacy in participants with PA

Clinical Trial Moderna Propionic Acidemia MRNA-3927 Genetic Disorder
BRIEF

published on 03/27/2024 at 11:35, 2 years 6 months ago

Moderna Announces Significant Advancements in Vaccine Development Programs

COVID-19 MRNA Technology Moderna Vaccine Development Phase 3 Clinical Trials

Published on 10/16/2026 at 08:00, 1 hour 51 minutes ago

Caledonia Mining Corporation Plc: Notification of Relevant Change to Significant Shareholder
Published on 10/16/2026 at 05:55, 3 hours 56 minutes ago

Collective Metals Announces Private Placement of Hard Dollar and Flow-Through Units
Published on 10/16/2026 at 02:10, 7 hours 41 minutes ago

Nova Scotia Silver Explorer TruSilver Metals Corp. Anticipates TSXV Trading Under "TAG" on October 27
Published on 10/16/2026 at 01:45, 8 hours 6 minutes ago

Faraday Copper Closes the Acquisition of the San Manuel Project in Arizona and Mobilizes Drill Rigs
Published on 10/16/2026 at 01:30, 8 hours 21 minutes ago

LNG Energy Group Announces Closing of Second Tranche of Private Placement

View all ACCESSWIRE

Published on 10/16/2026 at 09:15, 36 minutes ago

INIU Expands Into Outdoor Power With New Rugged Series
Published on 10/16/2026 at 09:00, 51 minutes ago

Original-Research: Antimony Resources Corp. (von GBC AG): BUY
Published on 10/16/2026 at 09:00, 51 minutes ago

Original-Research: OHB SE (von NuWays AG): BUY
Published on 10/16/2026 at 09:00, 51 minutes ago

Official List Notice
Published on 10/16/2026 at 08:00, 1 hour 51 minutes ago

Aquis Stock Exchange: Suspension of trading

View all EQS

Published on 10/16/2026 at 07:30, 2 hours 21 minutes ago

Third Quarter Revenues 2026
Published on 10/15/2026 at 18:50, 15 hours 1 minute ago

September & first 9 months of 2026 traffic figures - Revision of Traffic assumptions for 2026
Published on 10/15/2026 at 17:45, 16 hours 6 minutes ago

DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 10/15/2026 at 17:45, 16 hours 6 minutes ago

VOGO : H1 2026 results.
Published on 10/15/2026 at 17:45, 16 hours 6 minutes ago

THERMADOR GROUPE : Q3 2026

View all LES ECHOS COMFI WIRE

News